Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology. 2016 Apr 25;34(19):2258-64.

Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. The Lancet Oncology. 2016 Nov 30;17(11):1543-57.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC cancer. 2016 May 31;16(1):339.

Chan DL, Espinoza D, Chan J, Lee A, Faisal W, Segelov E, Pavlakis N. Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer. The Cochrane Library. 2016.

Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavlakis N, Gibbs P. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert review of anticancer therapy. 2016 May 3;16(5):557-71.

Pangon L, Ng I, Giry-Laterriere M, Currey N, Morgan A, Benthani F, Tran PN, Al-Sohaily S, Segelov E, Parker BL, Cowley MJ. JRK is a positive regulator of [beta]-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. Oncogene. 2016 Jun 2;35(22):2834-42.

Woodward N, White M, Pugliano L, Tsoi D, Ryan C. Management of patients treated with pertuzumab in the Australian clinical practice setting. Asia‐Pacific Journal of Clinical Oncology. 2016 Jun 1;12(S2):5-15.

Isaacs C, O’Regan R, Xu B, Masuda N, Arena F, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M. Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British journal of cancer. 2016 Mar 1;114(5):505.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, Azad AA, Wong S, Rosenthal M, Gibbs P, Tran B. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma. Internal medicine journal. 2016 Nov 1;46(11):1291-7.

Park ES, Jin C, Guo Q, Ang RR, Duffy SP, Matthews K, Azad A, Abdi H, Todenhöfer T, Bazov J, Chi KN. Continuous Flow Deformability‐Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets. Small. 2016 Apr 1;12(14):1909-19.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA oncology. 2016 Dec 1;2(12):1598-606.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome biology. 2016 Jan 26;17(1):10.

Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular oncology. 2016 May 31;10(5):693-703.

Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT, Chi KN, Joshua AM. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. Journal of translational medicine. 2016 Jan 13;14(1):12.

Muscat A, Popovski D, Jayasekara WS, Rossello FJ, Ferguson M, Marini KD, Alamgeer M, Algar EM, Downie P, Watkins DN, Cain JE. Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clinical Cancer Research. 2016 Jul 15;22(14):3560-70.

Powles, T. B., B. Escudier, P. de Souza, S. Chowdhury, D. Pook, U. Harmenberg, N. Basappa et al. “Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial.” (2016): 814P.

Delahunty R, Gan CL, Parente P, Pook D, Pezaro C. ‘changing Lanes’: Real-time Chemotherapy Switching In Advanced Prostate Cancer. Asia-pacific Journal of Clinical Oncology. 2016 Jul 1;12:34.

Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Harris M, van Kuilenburg AB, Mead S, Cameron A, Helsby N, George R. Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. European Journal of Pharmaceutical Sciences. 2016 Jan 1;81:36-41.

Meiser B, Quinn V, Gleeson M, Kirk J, Tucker K, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed ME, Barlow Stewart K, Field M, Harris M, Antill YC, Mitchell G. When knowledge of a heritable gene mutation comes out of the blue :Treatment-focused genetic testing in women newly diagnosed with breast cancer. European Journal of Human Genetics 2016 24:1517-1523.

Chiorean EG, Von Hoff D, Tabernero J, El Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D. Second line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. British Journal of Cancer 2016,225:188-194.

Yoong J, Chandra RV, William L, Franco M, Goldschlager T, Runacres F, Poon P. Percutaneous Sacroplasty for Painful Bone Metastases: A Case Report. Pain Practice. 2016 Dec 1.

Robinson S, Kissane D, Brooker J, Hempton C, Michael N, Fischer J, Franco M, Sulistio M, Clarke DM, Ozmen M, Burney S. Refinement and revalidation of the demoralization scale: The DS‐II—external validity. Cancer. 2016 Jul 15;122(14):2260-7.